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Secretory phospholipases A2 (sPLA2) exert proinflammatory actions through lipid mediators. These enzymes have been found to
be elevated in many inflammatory disorders such as rheumatoid arthritis, sepsis, and atherosclerosis. The aim of this study was to
evaluate the effect of harpalycin 2 (Har2), an isoflavone isolated from Harpalyce brasiliana Benth., in the enzymatic, edematogenic,
and myotoxic activities of sPLA2 from Bothrops pirajai, Crotalus durissus terrificus, Apis mellifera, and Naja naja venoms. Har2
inhibits all sPLA2 tested. PrTX-III (B. pirajai venom) was inhibited at about 58.7%, Cdt F15 (C. d. terrificus venom) at 78.8%, Apis
(from bee venom) at 87.7%, and Naja (N. naja venom) at 88.1%. Edema induced by exogenous sPLA2 administration performed in
mice paws showed significant inhibition by Har2 at the initial step. In addition, Har2 also inhibited the myotoxic activity of these
sPLA2s. In order to understand how Har2 interacts with these enzymes, docking calculations were made, indicating that the
residues His48 and Asp49 in the active site of these enzymes interacted powerfully with Har2 through hydrogen bonds. These data
pointed to a possible anti-inflammatory activity of Har2 through sPLA2 inhibition.
1. Introduction
The flavonoids are a group of plant secondary metabolites
widely distributed in nature. They are divided in two main
classes: the flavonoids and the isoflavonoids. Many pharma-
cological activities have been described for both classes such
as anti-inflammatory and antioxidant, antiallergic, antiviral,
and anticancer [1, 2]. Many works have shown the phos-
pholipase A2 (PLA2) inhibitory effects of flavonoids such as
rutin [3], morin [4], and quercetin [5], however, only few
works have been shown the antiphospholipasic A2 activity of
isoflavonoids [6].
The PLA2 s are a class of enzymes (EC 3.1.1.4) that cat-
alyzes the hydrolysis of the sn-2 ester bond of phospholipids
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to produce lysophospholipids and free fatty acids, which are
substrates for the synthesis of proinflammatory eicosanoids
and platelet aggregating factor (PAF) [7, 8], in addition to
reactive oxygen species produced during the synthesis of
eicosanoids (which play a role as a positive feedback of
the enzymatic active of the PLA2) [9]. They are divided in
two major groups: cytosolic phospholipase A2 (cPLA2) and
secretory phospholipase A2 (sPLA2). The last are divided in
ten groups as discussed elsewhere [10]. In many inflamma-
tory diseases, as in sepsis, atherosclerosis, and rheumatoid
arthritis, group IIA sPLA2 are found in the inflammatory
areas and play a role not fully understood up to date [11, 12].
The sPLA2 present in animal venoms share structural
features with mammalian (including human) group IIA
sPLA2, mainly in the active site, being for that reason useful
tools for the study of sPLA2 inhibitors [7–12]. The exogenous
administration of these enzymes to experimental animals
provokes an inflammatory response similar to that observed
with administration of endogenous sPLA2, besides more
specific responses as myonecrosis [5, 13].
Current anti-inflammatory therapies include nons-
teroidal anti-inflammatory drugs that inhibit either LOX
or COX-1/2 enzymes and have serious side effects such
as gastrointestinal ulceration, bleeding, and cardiovascular
complications. In addition to these problems, COX-1/2
and LOX inhibitors cannot regulate the production of the
PAF, which continues causing inflammation [7, 8]. Effective
inhibitors of sPLA2 could be capable of depleting the down-
stream proinflammatory metabolites of arachidonic acid as
well as PAF, without the adverse effects of the current corti-
costeroids therapy since these enzymes are secreted only in
pathological conditions [7–10].
Harpalyce brasiliana Benth. (Fabaceae) is a Brazilian folk
medicine, popularly known as “raiz-de-cobra” (Port. Lit.
snakeroot). Its roots have been used in the Northeast of Brazil
to treat snakebite [14], while its leaves are claimed to be
anti-inflammatory (personal unpublished data). In this
paper, the effect of harpalycin 2 in structure and enzymatic,
edematogenic, and myotoxic activities of four sPLA2 isolated
from animal venoms was evaluated. In addition, the analysis
of the interaction between harpalycin 2 and the active site of
the tested sPLA2 was performed by docking calculations.
2. Material and Methods
2.1. Material. Secretory PLA2 from Bothrops pirajai (PrTx-
III) and Crotalus durissus terrificus (Cdt F15) were purified as
described by Toyama et al. [15, 16], respectively. sPLA2 from
Apis mellifera venom was purchased from BIOMOL Interna-
tional. Bovine pancreas and Naja naja venom sPLA2 were
purchased from Sigma-Aldrich. The COX-1, COX-2, LOX
15hrc, and LOX 15syP1 came from Cayman Chemical. Other
salts, reagents, solvents were ultrapure grade, HPLC grade, or
sequencing grade purchase from the BIORAD, Sigma-
Aldrich (Supelco) and Pharmacia.
2.2. Plant Material. Leaves of Harpalyce brasiliana Benth.
were collected at the Chapada do Araripe, Barbalha (Ceará,
Brazil) by Prof. E. R. Silveira. Botanical authentication was
made by Prof. E. P. Nunes of the Department of Biology,
Federal University of Ceará. Voucher specimen (number:
32525) has been deposited at the Prisco Bezerra Herbarium
(EAC), Department de Biology, Federal University of Ceará,
Fortaleza (Ceará, Brazil).
2.3. General Procedures. The mass spectra were obtained
on a Hewlett-Packard 5971 mass spectrometer by electron
impact ionization (70 eV). 1H and 13C NMR spectra were
recorded on a Bruker Avance DRX-500 (500 MHz for 1H
and 125 MHz for 13C); chemical shifts were expressedin scale
and were referenced to residual DMSO (2.5 and 39.5 ppm).
Silica Gel 60 (Merck, 70–230 mesh) was used for analytical
TLC. Column chromatographies were performed over silica
gel (Merck, 60 F254 230–400 mesh).
2.4. Extraction and Isolation of Harpalycin 2. Leaves of
Harpalyce brasiliana were pulverized and extracted with
EtOH at room temperature. The solvent was removed under
reduced pressure which produced a dark viscous extract
(HBFE). Liquid-liquid partition of a water suspension of
HBFE (110 g) using petrol ether, CHCl3, EtOAc, and n-
BuOH yielded five fractions after solvent evaporation:
HBFEEp (24.5 g), HBFEC (22.4 g), HBFEA (6.8 g), HBFEB
(30.4 g), and HBFEAq (21.2 g).
Flash chromatography of HBFEC (12.0 g) using n-
hexane and EtOAc as binary mixtures of increasing polarity
afforded 30 fractions, which were pooled in 9 fractions
after thin layer chromatography (TLC) analysis. HBFEC
(10–12) presented a yellow precipitate, yielding 120.0 mg
after recrystallization. NMR and Mass-spectrometric analysis
showed the structure of the isoflavone harpalycin 2 (Har2).
The fractions HBFEC (8-9) and HBFEC (13–17) were
purified, using the same method, yielding more 200.0 mg of
Har2.
2.5. Inhibition of sPLA2 Activity. sPLA2 activity was measured
following the protocols described by Hernandez-Oliveira
et al. [17] and modified by Toyama et al. [18] for 96-
well plate. The standard assay mixture contained 200 mL of
buffer (10 mM Tris-HCl, 10 mM CaCl2, 100 mM, and NaCl,
pH 7.8), 20 µL of substrate (4-nitro-3-octanoyloxy-benzoic
acid (4N3OBA) 1 mg/mL, manufactured by BIOMOL, USA),
20 µL of water, and 20 µL of sPLA2 solution (1 mg/mL).
Enzymatic activity was calculated based on the increase in
absorbance at 425 nm after 20 min, at 37◦C, as a direct result
of the cleavage of the synthetic substrate. All assays were
done using n = 12 and absorbance was measured using a
SpectraMax 340 multiwell plate reader (Molecular Devices,
Sunnyvale, CA). Evaluation of Har2 effect on sPLA2 enzy-
matic activity was performed after incubation of Bothrops
pirajai (PrTx-III), Crotalus durissis terrificus (Cdt F15), Apis
mellifera (purified, without the mellitin component), and
Naja naja sPLA2 with Har2 at equal mass (1 : 1; w : w) for a
period of 30 minutes. The final concentration of the inhibitor
in the reaction mixture was the same of the substrate due to
the kinetic behavior of the sPLA2.
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2.6. Animals. Male Swiss mice (20–25 g) obtained from the
Animal Facilities of Federal University of Ceará were used
in this study. The animals were maintained under standard
conditions (22 ± 2◦C; 12 h light/dark cycle) with food
and water ad libitum. All experiments with animals were
guided in accordance with Brazilian laws for Care and Use
of Laboratory Animals and all the study protocols were
approved by Committee of Ethics from Federal University of
Ceará (Fortaleza, Brazil) protocol number 68/08.
2.7. Neutralization of the Edema Inducing Activity. Neutral-
ization of sPLA2-induced paw edema by Har2 was performed
according to Iglesias et al. [4], using male Swiss mice (20–
25 g, n = 6). The edema was induced by a single subplantar
injection of 25 µL of sPLA2 (25 µg/paw). Paw volume was
measured immediately before the injection of the samples
and at selected time intervals thereafter (30, 60, 120, 240, and
480 minutes) using a plethysmometer (Ugo Basile, Italy).
All samples were dissolved in sterile PBS. Results were
expressed as the increase in paw volume (µL) and calculated
by subtracting the basal volume. Evaluation of Har2 effect on
sPLA2 edema-inducing activity was carried out after incuba-
tion of Bothrops pirajai (PrTx-III), Crotalus durissis terrificus
(Cdt F15), Apis mellifera (purified, without the mellitin com-
ponent), and Naja naja sPLA2 with Har2 at equal mass (1 : 1;
w : w) for 30 minutes at 37◦C. The negative controls were
performed by administration of Har2 (25 µg/paw). These
values were subtracted from the volume of the paws treated
with sPLA2 incubated with Har2 for clarity reasons.
2.8. Neutralization of Myotoxic Activity. Plasma creatine
kinase (CK) activity was measured using a CK-UV kinetic kit
(Sigma Chemical Co.). Native sPLA2 (1 mg/mL) or those
previously incubated with Har2, as described above, were
injected intramuscularly (25 µL) in the gastrocnemius of
male Swiss mice (20–25 g, n = 6). The control group was
injected with sterile PBS, and the negative control with Har2.
After 3 hours, a blood sample was collected from the tails
using heparinized capillary tubes and centrifuged for plasma
separation. CK activity was determined in triplicate using
4 µL of plasma according to the manufacturer’s instructions,
and its activity was expressed in U/L.
2.9. Characterization of IC50 of Har2 against Several sPLA2
and Inflammatory Enzymes. The inhibitory capability of
Har2 against COX-1/2, LOX 15hrc, and 15syP1, bovine pan-
creas, and human group V sPLA2 was investigated according
to the manufacturer’s instructions (Cayman Chemical). All
assays were carried out using n = 12 and the data
measured using a SpectraMax 340 multiwell plate reader
(Molecular Devices, Sunnyvale, CA). Har2 was added in
different concentrations and IC50 values were calculated
using GraphPad Prism 5.0.
2.10. Circular Dichroism Spectroscopy. Native sPLA2, and
Har2-treated sPLA2 were dissolved in 10 mM sodium phos-
phate buffer (pH 7.4) and final protein concentrations were
adjusted to 8.7 mM. After centrifugation at 4000 g for 5 min,
samples of 20 µL were injected into molecular exclusion
column TSK G4000SWXL (0.7 × 300 mm) coupled in the
LC-2000Plus Series HPLC Systems (Jasco, USA), which have
been previously equilibrated with same buffer used for the
preparation of the samples sPLA2, Har2-treated sPLA2. In
this case, the chromatographic run of each samples was
simultaneously monitored using a CD-2095 Circular Dichro-
ism HPLC detector (Jasco, USA), FP-2020 Fluorescence
detector, and UV-2075 190 to 600 nm detector. Circular
dichroism spectra were obtained by adjust the wavelength
range 220–260 nm and 260–320 nm to measure the presence
of random coil and tertiary protein folding, respectively.
Data collection was performed with a bandwidth of 1 nm,
response time of 1 s at room temperature with 100 nm/min
scanning speed. The fluorescence detection was adjusted
specifically for monitoring the fluorescence emission of
tryptophan, which was measured between 300 and 450 nm
after excitation at 280 nm.
2.11. Molecular Modeling (Docking). The structural opti-
mization of the harpalycin 2 ligand was initially achieved
using the AM1 method [19] implemented in the BioMed-
Cache program (BioMedCache, 1989) with default values
for the convergence criteria. Docking calculations were per-
formed with the GOLD 4.0 program [20] in order to obtain
the relative in silico affinities of the Har2 ligand with respect
to the sPLA2 targets. The sPLA2 structures were taken from
the RCSB Protein Data Bank (http://www.pdb.org/), under
the PDB ID: 1GMZ, 2QOG, 1PSH, and 1POC, respectively,
for PrTX-III, Cdt F15, Naja, and Apis.
The docking calculations were performed taking advan-
tage of the flexibility of the Har2 ligand, by activating its
rotational degrees of freedom. The active site was defined
as all atoms within a radius of 10.0 Å from the residue 48
(His or Asp), which is an important residue according to the
literature [21, 22].
2.12. Statistical Analysis. Results were expressed as the mean
± SEM of replicated experiments. The significance of differ-
ences between means was assessed by an analysis of variance,
followed by a Dunnett’s test where several experimental
groups were compared with the control group. The confi-
dence limit for significance was set at P < 0.05.
3. Results and Discussion
Natural products from plants are of potential interest for the
treatment of a number of inflammatory diseases. They serve
as template molecules for the development of new drugs
and prototypes [12]. Flavonoids are polyphenolic com-
pounds widely distributed in plants. Due to their various
effects on immune and inflammatory systems, these com-
pounds are currently of great pharmacological interest [3].
There are several reports demonstrating that flavonoids are
able to inhibit PLA2 activity, arachidonic acid release, and
the formation of arachidonic acid metabolites [3, 4, 13].
In particular, isoflavones have also been reported to show







Figure 1: The structure of harpalycin 2.
anti-inflammatory activities, including inhibition of phos-
pholipases A2 and COX-1/2 [17, 18]. Harpalycin 2 (Har2)
was isolated as a white amorphous solid with m.p. 232.6–
234.4◦C. Its molecular formula of C21H18O7 was established
by the molecular ion at m/z 382 Daltons in the MS spec-
trum. Structure elucidation was performed by spectroscopic
means, including 1D and 2D NMR, and comparison with the
data from literature [14]. The structure of Har2 is shown in
Figure 1.
Group IIA secretory phospholipases A2 may be cat-
alytically active or inactive depending on the amino acid
residue 49. In catalytically active isoforms, this residue is
occupied by an aspartic acid [24]. Cotrim et al. [5] showed
through docking calculations that the chemical treatment of
crotoxin B (Cdt F15) with quercetin lead to an inhibition
of enzymatic activity due to the fact that quercetin binds
in the vicinity of His48 and Asp49 residues. Herein, Har2
inhibits all sPLA2 tested when the treatment was made before
the substrate addiction, with percentages of inhibition at
about 58.7% for PrTX-III, at 78.8% for Cdt F15, at 87.7%
for Apis, and at 88.1% for Naja secretory phospholipase A2
(Figure 2). These percentages of inhibition were greater than
p-bromophenacyl bromide (∼40%), a well-known sPLA2
inhibitor [5].
Neutralization of edema induced by exogenous sPLA2
administration performed in mice paws by harpalycin 2
showed significant inhibition of the edema initial step
induced by PrTX-III, Cdt F15, Apis, and Naja (Figure 3).
This first step is correlated with histamine/serotonin involve-
ment [24]. The edema-inducing effect of sPLA2 s could be
attributed to their ability to hydrolyse phospholipids; how-
ever Lys49 phospholipase A2-homologues can also induce
edema in the absence of PLA2 activity, which implies a
different mechanism of action for this pharmacological effect
[24]. In this case, all sPLA2 tested were catalytic active and
the partial inhibition of edema formation may be correlated
to the inhibition of phospholipids catalysis by the isoflavone.
Harpalycin 2 was able to inhibit the myotoxic activity of
the venom secretory phospholipases A2 tested in this study
(Figure 4), which is a pharmacological activity shared by
several types of snake venom sPLA2 [25]. This model, when
studied using Asp49 sPLA2, is interesting for evaluation of
the interfacial activation of the sPLA2s, since myotoxicity
is directed linked with enzymatic activity in the catalytic
sPLA2 isoforms [7]. Recently, involvement of potassium,
ATP, calcium, and purinergic receptors in the myotoxic
activity of snake venom sPLA2 was described by Cintra-
Francischinelli et al. [23]. The authors emphasized the role


















Figure 2: Effect of harpalycin 2 (Har2) on enzymatic activity of
sPLA2 from Bothrops pirajai (PrTX-III), Crotalus durissus terrificus
(Cdt F15), Apis mellifera (Apis), and Naja naja (Naja) venom
expressed as initial velocity of reaction after 20 min (Vo). (a)
Native sPLA2 enzymatic activity and (b) harpalycin 2 treated sPLA2
enzymatic activity. Data expressed as mean ± S.E.M. and analyzed
by ANOVA followed by Dunnett’s test, with ∗P set at 0.05.
of the purinergic receptor P2X and its inhibitors in the extent
of muscle tissue damage, giving an additional explanation to
the finding that the antitrypanosomal drug suramin provides
protection from the toxic effect of the Lys49 myotoxins of the
Bothrops jararacussu and Bothrops asper venoms. Suramin
also binds to P2X channels, and this property could, at least
in part, account for its myotoxic inhibitory activity. Several
flavonoids and isoflavones antagonize purinergic receptors
[26] which could explain in part the inhibitory effect of these
compounds in the myotoxic activity of snake venom sPLA2.
In order to elucidate the anti-inflammatory activity of
harpalycin 2, we further examined the ability of Har2 to
inhibit the enzymatic activity of COX-1/2 and LOX 15hrc
and 15syP1 as well as bovine pancreas PLA2 and human
group V PLA2. Har2 showed lower IC50 values for both
bovine and human sPLA2 than for COX-1/2 and LOX
enzymes, as shown in Table 1. These results showed that
harpalycin 2 has probably more affinity for sPLA2 than for
other proinflammatory enzymes.
Aiming to understand how harpalycin 2 interacts with
these sPLA2s, CD spectroscopy, fluorescence analysis, and
docking calculations were performed. Fluorescence profile
analysis of Har2, sPLA2s, and Har2:sPLA2s showed signifi-
cant changes in the spectral fluorescence profile among Har2
and the sPLA2 treated with Har2. CD analysis of native
and Har2-treated sPLA2 revealed that the treatment induced
discrete unfolding of sPLA2, which did not modify the
tridimensional structure of the proteins (See supplementary
material, available at doi: 10.1155/2012/987517).
The sPLA2 structures were represented by the PDB IDs
1GMZ, 2QOG, 1PSH, and 1POC, respectively, for PrTX-III,
Cdt F15, Naja, and Apis. The calculated docking score values












































































Figure 3: Effect of harpalycin 2 (Har2) on edema formation after a single subplantar injection of sPLA2 (25 µg/paw) from (a) Bothrops pirajai
(PrTX-III), (b) Crotalus durissus terrificus (Cdt F15), (c) Apis mellifera (Apis), and (d) Naja naja (Naja) venom expressed as the increase in
paw volume (µL). Native sPLA2 edematogenic activity is represented by circles whereas harpalycin 2 treated sPLA2 edematogenic activity is
showed as squares. Data expressed as mean ± S.E.M. and analyzed by ANOVA followed by Dunnett’s test, with ∗P set at 0.05.










Note: PrTX-III (piratoxin-III); BPPLA2 (bovine pancreas PLA2);
HGVPLA2 (human group V PLA2); COX-1 (cyclooxygenase-1); COX-2
(cyclooxygenase-2); LOX 15HRC (Lipoxygenase 15hrc); LOX 15SY (Lipoxy-
genase 15sy). N/D (Not determined).
(GOLD scores) for these targets were 33.93, 44.12, 55.26, and
51.23, respectively, for PrTX-III, Cdt F15, Naja, and Apis.
One can see in Figure 5 that an interesting trend between
the in silico (docking scores) and in vitro (percentages of
inhibition) results was observed. This means that greater sta-
bility (the most positive docking score values) of the complex
between the harpalycin 2 and the four sPLA2 enzymes is
related to greater inhibition percentage of the enzymatic
activities. Thus, harpalycin 2 has inhibitory capacity against
the enzymatic, edematogenic, and myotoxic activities from
neurotoxic venom secretory phospholipases A2, probably
due to the interaction with residues 48 and 49 in the active
site of these toxins. Comparing the amino acid sequences
alignment performed by Clustal X [27] among the four
sPLA2, we found that the Apis has a more specific sequence
(with an identity of 24% as compared with PrTX-III) while















PrTX-III Cdt F15 Apis Naja
sPLA2
sPLA2 + Har2
Figure 4: Inhibition of myotoxic activity of sPLA2 (25 µg/mice) from Bothrops pirajai (PrTX-III), Crotalus durissus terrificus (Cdt F15), Apis
mellifera (Apis) and Naja naja (Naja) venom expressed as creatine kinase release on plasma. (a) Native sPLA2 myotoxicity and (b) harpalycin

































Figure 5: Trend between docking scores performed by GOLD 4.0 (in silico) and percentages of inhibition of the enzymatic activity (in vitro).
The values near the points represent the percentage of inhibition for each PLA2, with the respective PDB ID below. The PDB ID: 1GMZ,
2QOG, 1PSH, and 1POC were used, respectively, for PrTX-III, Cdt F15, Naja, and Apis.
the other three sequences are similar to each other (identity
values of 44% for Naja and 57% for Cdt F15, when compared
to PrTX-III), Figure 6(a). Considering the secondary and
tertiary structures, the difference between the Apis and the
others is more relevant. Therefore, we performed a structural
alignment only for PrTX-III, Cdt F15, and Naja, using
PyMOL [28], as shown in Figure 6(b). The great similarity
among these three PLA2 is probably related to their evolu-
tionary origin from snake venoms, where PrTX-III and Cdt
F15 are classified as GIIA, while Naja is classified as GIA).
Using the 1PSH (Naja) target as example, because it repre-
sents the best result, a detailed inspection for the molecular
reasons of the good inhibition behavior of the harpalycin 2
in this target can be found in Figure 7. The most important
residues in the active site, including HIS48 and ASP49, are
labeled and are involved in polar interactions with harpalycin
2.
This data corroborates both ethnopharmacological uses
of this plant by Brazilian northeast population: the treatment
of snake bites, as sPLA2 s are the main toxins in these venoms
and, and as anti-inflammatory, due to the main role of sPLA2
in the inflammatory cascade of events. The data also pointed
to a possible anti-inflammatory activity of this isoflavone
mainly in disorders which involve sPLA2, such as asthma and
rheumatoid arthritis.
Abbreviations
Cdt F15: Crotoxin B from Crotalus durissus terrificus
COX-1/2: Cyclooxygenase-1/2
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(a)
(b)
Figure 6: (a) Multiple sequence alignment of PrTX-III, Cdt F15, Naja and Apis, with the PDB ID: 1GMZ, 2QOG, 1PSH and 1POC,
respectively. ClustalX was used with default setup. (b) Structure alignment of the PLA2 (cartoon model) with their respective docking









Figure 7: Panoramic (a) and detailed (b) view of the best docking solution obtained with the 1PSH (Naja) target. Important residues,
directly involved in intermolecular interactions with the inhibitor (harpalycin 2), are labeled. The Ca2+ atom of the catalytic center was also
represented in the figure.
CK: Creatine kinase
gVPLA2: Group V phospholipase A2
Har2: Harpalycin 2
LOX: Lipoxygenase
PAF: Platelet activation factor
PLA2: Phospholipase A2
PrTX-III: Piratoxin-III
sPLA2: Secretory phospholipase A2.
8 Evidence-Based Complementary and Alternative Medicine
Authors’ Contribution
R. M. Ximenes and M. M. Rabello have contributed equally
to this work.
Acknowledgments
This work was financially supported by CAPES (Conselho
de Aperfeiçoamento de Pessoal de Ensino Superior), CNPq
(Conselho Nacional de Desenvolvimento Cientı́fico e Tec-
nológico), FAPESP (Fundação de Amparo a Pesquisa do
Estado de São Paulo), and FUNCAP (Fundação Cearense de
Apoio a Pesquisa). The authors would like to thank Sidney
Ann Pratt for language revision.
References
[1] A. Garcı́a-Lafuente, E. Guillamón, A. Villares, M. A. Rostagno,
and J. A. Martı́nez, “Flavonoids as anti-inflammatory agents:
implications in cancer and cardiovascular disease,” Inflamma-
tion Research, vol. 58, no. 9, pp. 537–552, 2009.
[2] B. H. Havsteen, “The biochemistry and medical significance
of the flavonoids,” Pharmacology and Therapeutics, vol. 96, no.
2-3, pp. 67–202, 2002.
[3] M. Lindahl and C. Tagesson, “Flavonoids as phospholipase
A2 inhibitors: importance of their structure for selective
inhibition of group II phospholipase A2,” Inflammation, vol.
21, no. 3, pp. 347–356, 1997.
[4] C. V. Iglesias, R. Aparicio, L. Rodrigues-Simioni et al., “Effects
of morin on snake venom phospholipase A2 (PLA2),” Toxicon,
vol. 46, no. 7, pp. 751–758, 2005.
[5] C. A. Cotrim, S. C. B. De Oliveira, E. B. S. Diz-Filho et al.,
“Quercetin as an inhibitor of snake venom secretory phospho-
lipase A2,” Chemico-Biological Interactions, vol. 189, no. 1-2,
pp. 9–16, 2011.
[6] K. K. Dharmappa, R. Mohamed, H. V. Shivaprasad, and B. S.
Vishwanath, “Genistein, a potent inhibitor of secretory phos-
pholipase A2: a new insight in down regulation of inflamma-
tion,” Inflammopharmacology, vol. 18, no. 1, pp. 25–31, 2010.
[7] G. Lambeau and M. H. Gelb, “Biochemistry and physiology
of mammalian secreted phospholipases A2,” Annual Review of
Biochemistry, vol. 77, pp. 495–520, 2008.
[8] B. B. Boyanovsky and N. R. Webb, “Biology of secretory phos-
pholipase A2,” Cardiovascular Drugs and Therapy, vol. 23, no.
1, pp. 61–72, 2009.
[9] B. L. Nanda, A. Nataraju, R. Rajesh, K. S. Rangappa, M. A.
Shekar, and B. S. Vishwanath, “PLA2 mediated arachidonate
free radicals: PLA2 inhibition and neutralization of free
radicals by anti-oxidants—a new role as anti-inflammatory
molecule,” Current Topics in Medicinal Chemistry, vol. 7, no.
8, pp. 765–777, 2007.
[10] J. E. Burke and E. A. Dennis, “Phospholipase A2 biochemistry,”
Cardiovascular Drugs and Therapy, vol. 23, no. 1, pp. 49–59,
2009.
[11] K. Hamaguchi, H. Kuwata, K. Yoshihara et al., “Induction of
distinct sets of secretory phospholipase A2 in rodents during
inflammation,” Biochimica et Biophysica Acta, vol. 1635, no. 1,
pp. 37–47, 2003.
[12] K. K. Dharmappa, R. V. Kumar, A. Nataraju, R. Mohamed,
H. V. Shivaprasad, and B. S. Vishwanath, “Anti-inflammatory
activity of oleanolic acid by inhibition of secretory phospholi-
pase A2,” Planta Medica, vol. 75, no. 3, pp. 211–215, 2009.
[13] B. Gil, M. J. Sanz, M. C. Terencio, R. Gunasegaran, M.
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